Second, targeting TMIGD2 with mAbs or knockdown of TMIGD2 exhibited slight effect on normal HSPCs self-renewal in vitro and hematopoiesis in vivo, suggesting that TMIGD2 is a feasible target for AML therapy. Here, TMIGD2 is linked to acute myeloid leukemia.